Brief: Seelos Therapeutics Says FDA Accepts IND Application And Grants Fast Track Designation For Spinocerebellar Ataxia Treatment
08/11/2021 13:24
Nov 8 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION AND GRANT OF FAST TRACK DESIGNATION FOR
SLS-005 (IV TREHALOSE) FOR THE TREATMENT OF SPINOCEREBELLAR
ATAXIA
* SEELOS THERAPEUTICS INC - GLOBAL PHASE IIB/III STUDY FOR
SLS-005
TO BE INITIATED IN EARLY 2022
Source text for Eikon: ID:nPn66pjdja
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio